Related Experiment Video
Updated: Oct 31, 2025

Crystal Structure of the N-terminal Domain of Ryanodine Receptor from Plutella xylostella
Published on: November 30, 2018
Crystal structures of HER3 extracellular domain 4 in complex with the designed ankyrin-repeat protein D5
Filip Radom1, Clemens Vonrhein2, Peer R E Mittl1
1Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland.
Abstract:
The members of the human epidermal growth factor receptor (HER) family are among the most intensely studied oncological targets. HER3 (ErbB3), which had long been neglected, has emerged as a key oncogene, regulating the activity of other receptors and being involved in progression and tumor escape in multiple types of cancer. Designed ankyrin-repeat proteins (DARPins) serve as antibody mimetics that have proven to be useful in the clinic, in diagnostics and in research. DARPins have previously been selected against EGFR (HER1), HER2 and HER4. In particular, their combination into bivalent binders that separate or lock receptors in their inactive conformation has proved to be a promising strategy for the design of potent anticancer therapeutics. Here, the selection of DARPins targeting extracellular domain 4 of HER3 (HER3d4) is described. One of the selected DARPins, D5, in complex with HER3d4 crystallized in two closely related crystal forms that diffracted to 2.3 and 2.0 Å resolution, respectively. The DARPin D5 epitope comprises HER3d4 residues 568-577. These residues also contribute to interactions within the tethered (inactive) and extended (active) conformations of the extracellular domain of HER3.
Insights
Researchers developed novel Designed Ankyrin-repeat Proteins (DARPins) targeting the human epidermal growth factor receptor 3 (HER3) extracellular domain. These DARPins show potential for developing new cancer therapeutics by inhibiting HER3 activity.
Area of Science:
- Oncology
- Molecular Biology
- Structural Biology
Background:
- The human epidermal growth factor receptor (HER) family, particularly HER3 (ErbB3), is crucial in cancer progression and tumor escape.
- Designed Ankyrin-repeat Proteins (DARPins) are effective antibody mimetics used in clinical and research settings.
- Previous DARPin development targeted EGFR, HER2, and HER4, with bivalent binders showing therapeutic promise.
Purpose of the Study:
- To select and characterize DARPins that specifically target the extracellular domain 4 (HER3d4) of HER3.
- To investigate the structural basis of DARPin-HER3 interaction for potential therapeutic applications.
Main Methods:
- Selection of DARPins against HER3d4.
- Crystallization of a selected DARPin (D5) in complex with HER3d4.
- X-ray diffraction to determine the crystal structure at 2.3 and 2.0 Å resolution.
Main Results:
- Successful selection of DARPins targeting HER3d4.
- The crystal structure revealed that DARPin D5 binds to HER3d4 residues 568-577.
- This epitope is involved in both inactive and active conformations of HER3, suggesting a mechanism for receptor modulation.
Conclusions:
- DARPins targeting HER3 are a viable strategy for developing novel cancer therapeutics.
- The structural insights into DARPin D5 binding provide a foundation for designing potent HER3-targeting drugs.
- Targeting HER3 with DARPins could offer a new approach to combatting various cancers.
Related Concept Videos
Structure of Cadherins
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Crystal Field Theory - Tetrahedral and Square Planar Complexes
Crystal field theory (CFT) is applicable to molecules in geometries other than octahedral. In octahedral complexes, the lobes of the dx2−y2 and dz2 orbitals point directly at the ligands. For tetrahedral complexes, the d orbitals remain in place, but with only four ligands located between the axes. None of the orbitals points directly at the tetrahedral ligands. However, the dx2−y2 and dz2 orbitals (along the Cartesian axes) overlap with the ligands less than the dxy,...

